147 related articles for article (PubMed ID: 36381289)
1. Genetic variation of the blood coagulation regulator tissue factor pathway inhibitor and venous thromboembolism among middle-aged and older adults: A population-based cohort study.
Manderstedt E; Lind-Halldén C; Halldén C; Elf J; Svensson PJ; Engström G; Melander O; Baras A; Lotta LA; Zöller B;
Res Pract Thromb Haemost; 2022 Oct; 6(7):e12842. PubMed ID: 36381289
[TBL] [Abstract][Full Text] [Related]
2. Thrombomodulin (THBD) gene variants and thrombotic risk in a population-based cohort study.
Manderstedt E; Halldén C; Lind-Halldén C; Elf J; Svensson PJ; Engström G; Melander O; Baras A; Lotta LA; Zöller B;
J Thromb Haemost; 2022 Apr; 20(4):929-935. PubMed ID: 34970867
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic Risk Determined by Protein C Receptor (PROCR) Variants among Middle-Aged and Older Adults: A Population-Based Cohort Study.
Manderstedt E; Halldén C; Lind-Halldén C; Elf J; Svensson PJ; Engström G; Melander O; Baras A; Lotta LA; Zöller B;
Thromb Haemost; 2022 Aug; 122(8):1326-1332. PubMed ID: 35021256
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic risk determined by rare and common SERPINA1 variants in a population-based cohort study.
Manderstedt E; Halldén C; Lind-Halldén C; Elf J; Svensson PJ; Engström G; Melander O; Baras A; Lotta LA; Zöller B;
J Thromb Haemost; 2022 Jun; 20(6):1421-1427. PubMed ID: 35263815
[TBL] [Abstract][Full Text] [Related]
5. Classic Thrombophilias and Thrombotic Risk Among Middle-Aged and Older Adults: A Population-Based Cohort Study.
Manderstedt E; Lind-Halldén C; Halldén C; Elf J; Svensson PJ; Dahlbäck B; Engström G; Melander O; Baras A; Lotta LA; Zöller B;
J Am Heart Assoc; 2022 Feb; 11(4):e023018. PubMed ID: 35112923
[TBL] [Abstract][Full Text] [Related]
6. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology.
Zakai NA; Lutsey PL; Folsom AR; Heckbert SR; Cushman M
Thromb Haemost; 2010 Aug; 104(2):207-12. PubMed ID: 20431849
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.
Englisch C; Moik F; Thaler J; Koder S; Mackman N; Preusser M; Pabinger I; Ay C
Haematologica; 2024 Apr; 109(4):1128-1136. PubMed ID: 37822244
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease.
Desch KC; Ozel AB; Halvorsen M; Jacobi PM; Golden K; Underwood M; Germain M; Tregouet DA; Reitsma PH; Kearon C; Mokry L; Richards JB; Williams F; Li JZ; Goldstein D; Ginsburg D
Blood; 2020 Jul; 136(5):533-541. PubMed ID: 32457982
[TBL] [Abstract][Full Text] [Related]
9. Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
Dennis J; Truong V; Aïssi D; Medina-Rivera A; Blankenberg S; Germain M; Lemire M; Antounians L; Civelek M; Schnabel R; Wells P; Wilson MD; Morange PE; Trégouët DA; Gagnon F
J Thromb Haemost; 2016 Oct; 14(10):1960-1970. PubMed ID: 27490645
[TBL] [Abstract][Full Text] [Related]
10. [Association of single nucleotide polymorphisms of tissue factor and tissue factor pathway inhibitor with venous thromboembolism in patients with lung cancer].
Zhang XL; Zhu J; Chen WH; Zhai ZG; Zhang YH
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(12):901-906. PubMed ID: 29665662
[No Abstract] [Full Text] [Related]
11. A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant.
Morange PE; Peiretti F; Gourhant L; Proust C; Soukarieh O; Pulcrano-Nicolas AS; Saripella GV; Stefanucci L; Lacroix R; Ibrahim-Kosta M; Lemarié CA; Frontini M; Alessi MC; Trégouët DA; Couturaud F
PLoS Genet; 2021 Jan; 17(1):e1009284. PubMed ID: 33465109
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.
Lincz LF; Adams MJ; Scorgie FE; Thom J; Baker RI; Seldon M
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532
[TBL] [Abstract][Full Text] [Related]
13. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
14. Whole exome sequencing identifies genetic variants in Chinese Han pregnant women with venous thromboembolism.
Shen Y; Zhang Y; Xiong Y; Zhang Z; Zhang B; Li A; Zhang Z; Ding J; Du J; Che Y
Thromb Res; 2022 Mar; 211():49-55. PubMed ID: 35074609
[TBL] [Abstract][Full Text] [Related]
15. Decreased anticoagulant response to tissue factor pathway inhibitor in patients with venous thromboembolism and otherwise no evidence of hereditary or acquired thrombophilia.
Bombeli T; Piccapietra B; Boersma J; Fehr J
Thromb Haemost; 2004 Jan; 91(1):80-6. PubMed ID: 14691572
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.
Hoke M; Kyrle PA; Minar E; Bialonzcyk C; Hirschl M; Schneider B; Kollars M; Weltermann A; Eichinger S
Thromb Haemost; 2005 Oct; 94(4):787-90. PubMed ID: 16270631
[TBL] [Abstract][Full Text] [Related]
17. Burden of rare exome sequence variants in PROC gene is associated with venous thromboembolism: a population-based study.
Tang W; Stimson MR; Basu S; Heckbert SR; Cushman M; Pankow JS; Folsom AR; Pankratz N
J Thromb Haemost; 2020 Feb; 18(2):445-453. PubMed ID: 31680443
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism.
Kwon A; Jo SH; Jo YA; Park JY; Kim M; Kang HJ; Kim HS; Cho HC; Lee YK
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):416-21. PubMed ID: 24448154
[TBL] [Abstract][Full Text] [Related]
19. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.
Abu Saadeh F; Norris L; O'Toole S; Mohamed BM; Langhe R; O'Leary J; Gleeson N
Thromb Res; 2013 Nov; 132(5):627-34. PubMed ID: 24094893
[TBL] [Abstract][Full Text] [Related]
20. High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism.
Damoah CE; Snir O; Hindberg K; Garred P; Ludviksen JK; Brækkan SK; Morelli VM; Mollnes TE; Hansen JB;
Arterioscler Thromb Vasc Biol; 2022 Sep; 42(9):1186-1197. PubMed ID: 35861070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
